FDA Panel Votes to Support CAR-T Therapies by Johnson & Johnson and Bristol Myers Squibb for Multiple Myeloma Treatment
Silver Spring, Maryland – An FDA advisory committee voted overwhelmingly in favor of recommending the approval of CAR-T therapies from Johnson & Johnson, Legend Biotech, Bristol Myers Squibb, and 2seventyBio for the treatment of multiple myeloma. The committee’s support for these therapies highlights a significant milestone in the ongoing discussions surrounding the use of CAR-T treatments in cancer care. During the committee meeting, concerns were raised about the higher rate of early deaths observed in …